Crotamiton
Eurax (crotamiton) is a small molecule pharmaceutical. Crotamiton was first approved as Eurax on 1982-01-01. It is used to treat pruritus and scabies in the USA. It is known to target transient receptor potential cation channel subfamily V member 4.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Eurax (generic drugs available since 1982-01-01)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Crotamiton
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EURAX | Journey Medical | N-009112 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| crotan | ANDA | 2020-01-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pruritus | HP_0000989 | D011537 | L29 |
| scabies | — | D012532 | B86 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adrenal insufficiency | D000309 | 1 | — | 1 | 2 | 7 | 11 | ||
| Post-dural puncture headache | D051299 | — | 1 | — | 1 | — | 2 | ||
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | — | — | 1 | — | 1 |
| Healthy volunteers/patients | — | — | — | — | 1 | — | 1 | ||
| Coronary artery disease | D003324 | I25.1 | — | — | — | 1 | — | 1 | |
| Mitral valve insufficiency | D008944 | HP_0001653 | — | — | — | 1 | — | 1 | |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | 1 | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | — | 1 | 2 |
| Infantile spasms | D013036 | EFO_1000643 | G40.82 | — | — | 1 | — | — | 1 |
| Lecithin cholesterol acyltransferase deficiency | D007863 | E78.6 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 1 | 2 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 1 | — | — | — | 1 | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Adrenal cortex diseases | D000303 | 1 | — | — | — | — | 1 | ||
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Addison disease | D000224 | E27.1 | — | — | — | — | 2 | 2 | |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | — | 1 | 1 |
| Adrenal gland neoplasms | D000310 | EFO_0003850 | C74 | — | — | — | — | 1 | 1 |
| Physiological stress | D013312 | — | — | — | — | 1 | 1 | ||
| Baroreflex | D017704 | — | — | — | — | 1 | 1 | ||
| Postural orthostatic tachycardia syndrome | D054972 | G90.A | — | — | — | — | 1 | 1 | |
| Autosomal dominant polycystic kidney | D016891 | EFO_1001496 | Q61.2 | — | — | — | — | 1 | 1 |
| Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | — | — | — | 1 | 1 |
| Craniocerebral trauma | D006259 | S00 | — | — | — | — | 1 | 1 | |
| Brain injuries | D001930 | S06.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CROTAMITON |
| INN | crotamiton |
| Description | Crotamiton is an enamide resulting from the formal condensation of crotonic acid with N-ethyl-2-methylaniline. A colourless or pale yellow oily liquid, it is used in the treatment of pruritus (itching) by producing a counter-irritation: as it evaporates from the skin, it produces a cooling effect that diverts attention away from the itching. It has also been used as an acaricide in the treatment of scabies, though more effective drugs are usually preferred. It has a role as an antipruritic drug and a scabicide. It is an enamide and a tertiary carboxamide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C/C=C/C(=O)N(CC)c1ccccc1C |
Identifiers
| PDB | — |
| CAS-ID | 124236-29-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200709 |
| ChEBI ID | — |
| PubChem CID | 688020 |
| DrugBank | DB00265 |
| UNII ID | D6S4O4XD0H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TRPV4
TRPV4
Organism
Homo sapiens
Gene name
TRPV4
Gene synonyms
VRL2, VROAC
NCBI Gene ID
Protein name
transient receptor potential cation channel subfamily V member 4
Protein synonyms
Osm-9-like TRP channel 4, OSM9-like transient receptor potential channel 4, osmosensitive transient receptor potential channel 4, OTRPC4, Transient receptor potential protein 12, TRP12, Vanilloid receptor-like channel 2, Vanilloid receptor-like protein 2, vanilloid receptor-related osmotically activated channel, Vanilloid receptor-related osmotically-activated channel, VR-OAC, VRL-2
Uniprot ID
Mouse ortholog
Trpv4 (63873)
transient receptor potential cation channel subfamily V member 4 (Q9ES76)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 334 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
124 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more